文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-DOTATATE PRRT在胃肠胰神经内分泌肿瘤患者中的安全性与危及器官剂量学:前瞻性2期LUMEN研究数据

177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.
PubMed 文献 · Clin Nucl Med · 2024-06-19

这项单臂前瞻性2期研究纳入37例胃肠胰神经内分泌肿瘤患者,评估177Lu-DOTATATE肽受体放射性核素治疗(PRRT)的毒性、危及器官剂量学与疾病进展的关联。最常见不良事件为贫血和淋巴细胞减少(各65%),≥3级淋巴细胞减少占43%,无≥3级肾毒性;肾小球滤过率中位下降11%(P<0.001),肾BED、骨髓BED及脾吸收剂量均与相应毒性无显著关联,无进展生存与肾功能下降或血液学毒性发生亦无关联。

要点

  • 37例胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATATE PRRT,最常见不良事件为贫血和淋巴细胞减少(各65%)。
  • ≥3级不良事件以淋巴细胞减少最常见(43%),未观察到≥3级肾毒性。
  • 肾BED与iGFR下降无相关性(Spearman ρ=-0.09),骨髓BED及脾吸收剂量与血液学毒性分级无显著关联。

核心结论

  • 本研究证实177Lu-DOTATATE PRRT在胃肠胰神经内分泌肿瘤患者中的安全性,与危及器官剂量学无关;肾脏、骨髓和脾的剂量学指标与肾脏或血液学毒性无关联。

研究设计与样本

  • 单臂、前瞻性、2期研究,纳入37例胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATATE PRRT。
  • 患者每6个月接受血液检查、同位素肾小球滤过率(iGFR)及影像学检查(CT/MRI和PET)随访直至疾病进展。
  • 按CTCAEv4.03收集治疗期间发生的不良事件并随访至缓解;每个PRRT周期后行肾脏生物有效剂量(BED)、骨髓BED及脾吸收剂量(AD)剂量学检测。

主要发现

  • 最常见不良事件为贫血和淋巴细胞减少(各65%),其次为血小板减少和乏力(各51%)、脱发(46%)、恶心(41%)。
  • 最常见≥3级不良事件为淋巴细胞减少(43%);无≥3级肾毒性。
  • 中位随访23个月时,iGFR中位下降11%(P<0.001)。
  • iGFR下降百分比与肾脏BED无相关性(Spearman ρ=-0.09)。
  • 骨髓BED或脾AD与血液学毒性分级之间无显著关联;无进展生存与PRRT期间肾功能下降或血液学毒性发生均无关联。

关键数值与推荐

  • 不良事件按CTCAEv4.03分级。
  • 中位随访23个月时iGFR中位下降11%(P<0.001)。
  • iGFR下降百分比与肾脏BED的Spearman ρ=-0.09。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess the association among toxicity, dosimetry of organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with 177 Lu-DOTATATE. PATIENTS AND METHODS: Thirty-seven patients with GEP-NETs underwent 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in a single-arm, prospective, phase 2 study, where patients were followed up with blood tests, isotopic glomerular filtration rate (iGFR), and imaging examinations (CT/MRI and PET) every 6 months until disease progression. Adverse events (AEs) graded per CTCAEv4.03 and occurring during treatment were collected and followed up until resolution. Dosimetry, including biologically effective doses (BEDs) to kidneys, BED to bone marrow, and absorbed dose (AD) to spleen, was performed after each PRRT cycle. Statistical analyses explored associations among dosimetry, toxicity, and patient progression free-survival. RESULTS: The most common AEs were anemia and lymphopenia (65%), followed by thrombocytopenia and fatigue (each 51%), alopecia (46%), and nausea (41%). The most common grade ≥3 AE was lymphopenia (43%). There was no grade ≥3 nephrotoxicity. The median iGFR % decrease was 11% ( P < 0.001), at a median follow-up of 23 months. iGFR %decrease and renal BED did not correlate (Spearman ρ = -0.09). Similarly, no significant association was found between bone marrow BED or spleen AD and the grades of hematological toxicities. We observed no association between progression free-survival and either the decline of renal function or the occurrence of hematological toxicities during PRRT. CONCLUSIONS: This study confirms the safety profile of 177 Lu-DOTATATE PRRT in patients with GEP-NETs irrespective of the dosimetry of organs at risk. Kidney, bone marrow, and spleen dosimetry measures were not associated with renal or hematological toxicity.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mileva M, Van Bogaert C, Marin G, et al. 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study. Clin Nucl Med. 2024. PMID: 38914016. doi:10.1097/RLU.0000000000005330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。